Known targets — ChEMBL curated mechanism
MMP1MMP13MMP7MMP8polrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Ethyl Acetate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | SI | P14410 | 1/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyl Acetate SCHEMBL7091348 | 0.97 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL2409419 | 0.97 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL6940297 | 0.97 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL287875 | 0.97 | ALDH1A1 (0.82) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL7622679 | 0.94 | ALDH1A1 (0.78) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL9329736 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL15546159 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL15443206 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL948368 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAHSD17B10TSHRALOX15 | |
| Ethyl Acetate SCHEMBL18492853 | 0.94 | ALDH1A1 (0.88) | ALDH1A1LMNAHSD17B10TSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104825872-B | A kind of room temperature preparation of eliminating pestilence and relieving toxicity Ultramicro-powder and thin-layer identification method | 河南省康星药业股份有限公司 | 2019-05-17 | — | — | CN | claimed |
| CN-104825872-A | Normal-temperature preparation and thin-layer identification method of ultrafine powder capable of clearing heat and removing toxicity | HENAN PROVINCE HEALTH STAR PHARMACEUTICAL CO LTD | 2015-08-12 | — | — | CN | claimed |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSTY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240024347-A1 | PRODRUGS OF 6-MERCAPTOPURINE | THE JOHNS HOPKINS UNIVERSTY | 2024-01-25 | — | — | US | disclosed |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-13 | — | — | US | disclosed |
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-05-10 | — | — | US | disclosed |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2020-12-24 | — | — | US | disclosed |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-01-28 | — | — | US | disclosed |
| CN-104825872-B | A kind of room temperature preparation of eliminating pestilence and relieving toxicity Ultramicro-powder and thin-layer identification method | 河南省康星药业股份有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-104825872-B | A kind of room temperature preparation of eliminating pestilence and relieving toxicity Ultramicro-powder and thin-layer identification method | 河南省康星药业股份有限公司 | 2019-05-17 | — | — | CN | disclosed |
| US-20180244705-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2018-08-30 | — | — | US | disclosed |
| US-9988407-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | THE JOHNS HOPKINS UNIVERSITY (US) | 2018-06-05 | — | — | US | disclosed |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2017100849-A1 | 6-OXOPURINE PHOSPHORIBOSYL TRANSFERASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-06-22 | — | — | WO | disclosed |
| CN-104825872-A | Normal-temperature preparation and thin-layer identification method of ultrafine powder capable of clearing heat and removing toxicity | HENAN PROVINCE HEALTH STAR PHARMACEUTICAL CO LTD | 2015-08-12 | — | — | CN | disclosed |
| CN-104825872-A | Normal-temperature preparation and thin-layer identification method of ultrafine powder capable of clearing heat and removing toxicity | HENAN PROVINCE HEALTH STAR PHARMACEUTICAL CO LTD | 2015-08-12 | — | — | CN | disclosed |
| CN-104725394-A | Method for preparing glabridin | LI YUSHAN | 2015-06-24 | — | — | CN | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11325931-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | ALDH1A1 796/4885LMNA 1683/4885HSD17B10 1728/4885 |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | ITPA, ZC3HAV1, MTAP | ALDH1A1 1877/4885LMNA 3440/4885HSD17B10 4540/4885 |
| US-20230115651-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | ALDH1A1 718/4885LMNA 1413/4885HSD17B10 1946/4885 |
| US-11932664-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | ALDH1A1 796/4885LMNA 1683/4885HSD17B10 1728/4885 |
| US-20170226141-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | ALDH1A1 796/4885LMNA 1683/4885HSD17B10 1728/4885 |
| US-20180244705-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | ALDH1A1 796/4885LMNA 1683/4885HSD17B10 1728/4885 |
| US-20200399298-A1 | PRODRUGS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR | FOLH1, KLK3, DNPEP | ALDH1A1 718/4885LMNA 1413/4885HSD17B10 1946/4885 |
| US-10544176-B2 | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor | FOLH1, KLK3, DNPEP | ALDH1A1 796/4885LMNA 1683/4885HSD17B10 1728/4885 |
| US-20240024347-A1 | PRODRUGS OF 6-MERCAPTOPURINE | TPMT, TYMP, MTAP | ALDH1A1 340/4885LMNA 4691/4885HSD17B10 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.